• AstraZeneca plc, of London, said it plans to conduct the EUCLID study, a global trial involving 11,500 patients with peripheral artery disease (PAD), to test Brilinta (ticagrelor) as a monotherapy, compared to Plavix (clopidogrel, Sanofi SA and Bristol-Myers Squibb Co.). EUCLID is designed to evaluate cardiovascular event rate and safety in PAD patients.

• Grifols SA, of Barcelona, Spain, said it plans to start a safety trial of an inhaled formulation of alpha1-proteinase inhibitor later this year. The product previously gained orphan drug designation in the U.S. for cystic fibrosis.